Skip to content
Home
Portfolio
People
Sustainability
News
Home
Portfolio
People
Sustainability
News
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
The latest news on
XGEN
and its companies.
Linkedin
Follow us on LinkedIn
Portfolio Company News
XGEN News
All Categories
Portfolio Company News - Press Release
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
February 6, 2026
iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
iOnctura bolsters leadership team with new appointments
February 6, 2026
iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
February 6, 2026
iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new nonclinical data at ASH
February 6, 2026
iOnctura
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia
February 6, 2026
Genespire
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts
February 6, 2026
Protembis
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
Tes Pharma Announces Appointment of Andrea Pellacani, MD, PhD, as Chief Medical Officer
February 6, 2026
Tes Pharma
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
Professor Pellicciari Awarded by President Mattarella with the Bronze Medal of Merit for Public Health
February 6, 2026
Tes Pharma
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....
Portfolio Company News - Press Release
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer
February 6, 2026
Nouscom
PAGE Therapeutics is a Swiss preclinical-stage biotechnology company spun out of ETH Zurich, based on the groundbreaking science of Prof....